Cytomegalovirus infection treatment market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline medicine which are promising by key market players for the treatment of CMV infection. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to fuel the growth of CMV infection treatment market. However, recent expiries of patented medicine, generic medicine that are available for the treatment like Ganciclovir & Foscarnet are anticipated to hamper the market growth of cytomegalovirus infection treatment.A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-cytomegalovirus-infection-treatment-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
The global cytomegalovirus infection market is classified on the basis of drug class, infection, distribution channel, and geography.
Based on drug class, the global cytomegalovirus infection market is segmented into the following:
Antiviral medicine
Foscarnet
Cytovene
Vistide
Others
Based on infection, the global cytomegalovirus infection market is segmented into the following
Retinitis
Pneumonia
Gastroenteritis
Others (Mouth Ulcers, Pharyngitis, etc.)
Based on distribution channel, the global cytomegalovirus infection market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Others
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-cytomegalovirus-infection-treatment-market/#ulp-c654SbFYO64MsOhu[/URL]
Global cytomegalovirus infection treatment market is anticipated to show effective growth rate in foresee period. Players in the market are heavily investing in R&D for the development of novel therapies and medicine to treat cytomegalovirus infection. Moreover, regulatory bodies of the healthcare sector are having more attention on novel medicine by giving faster approvals and special status for the medicine. For instance, Merck & Co. Inc., developed Letermovir, antiviral drug for the treatment of CMV infection. The drug has received fast track status by the U.S. FDA and the orphan drug status by European Medicines Agency.
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-cytomegalovirus-infection-treatment-market/#ulp-14mlyhjMGhVjZqa3[/URL]
On the basis of Geographical regions, CMV infection treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. North America & Europe were anticipated to contribute major share in the cytomegalovirus infection treatment market due to the high prevalence rate of cytomegalovirus infection. As per Centre for Disease Control and Prevention (CDC), approximately, 80,000 cases of CMV infections were diagnosed in U.S. and Europe.
Some of the players in cytomegalovirus infection market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), AiCuris Anti-infective Cures GmbH (Germany) Vical, Inc. (U.S.), Chimerix, Inc. (U.S.) and ViroPharma (U.S.), to name a few
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553"